Mizuho Markets Americas LLC Decreases Position in West Pharmaceutical Services, Inc. $WST

Mizuho Markets Americas LLC lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 69.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 1,141 shares of the medical instruments supplier’s stock after selling 2,562 shares during the quarter. Mizuho Markets Americas LLC’s holdings in West Pharmaceutical Services were worth $250,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Zions Bancorporation National Association UT purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $25,000. Quarry LP purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. First Horizon Advisors Inc. increased its stake in shares of West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 85 shares during the last quarter. CVA Family Office LLC increased its stake in shares of West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 172 shares during the last quarter. Finally, Cromwell Holdings LLC increased its stake in shares of West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 188 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 1.3%

Shares of NYSE:WST opened at $283.54 on Wednesday. The firm has a fifty day moving average price of $260.89 and a two-hundred day moving average price of $235.79. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $348.90. The company has a market cap of $20.40 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 4.12 and a beta of 1.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The firm had revenue of $804.60 million during the quarter, compared to the consensus estimate of $788.42 million. During the same period last year, the firm earned $1.85 EPS. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on WST. Barclays raised their price target on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research note on Monday. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft set a $345.00 price objective on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday. UBS Group lifted their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday. Finally, Rothschild Redb upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $349.11.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.